Nanobiotix Resumes Trading of Ordinary Shares on Euronext Paris

Nanobiotix, a biotechnology firm at the late-clinical stage, announced the resumption of trading for its ordinary shares on Euronext Paris. The trading halt occurred earlier on May 21, 2026, at the company's request. The suspension was linked to the announcement of a Global Offering, including public offerings in the US and Europe, to finalize investor allocations and pricing. Trading resumed at 3:30 p.m. in Paris.

The company's strategy involves pioneering physics-based methods for cancer and major disease treatments. Founded in 2003, Nanobiotix is headquartered in Paris with listings on Euronext and Nasdaq. Their patents cover nanotechnology applications in oncology, bioavailability, and the central nervous system field.